Search Result

Results for "

locomotor activity

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (3) Adrenergic Receptor (6) Cannabinoid Receptor (2) Cholinesterase (ChE) (1) Dopamine Receptor (16) Dopamine Transporter (1) Drug Intermediate (1) Drug Isomer (1) EAAT (1) GABA Receptor (1) HDAC (1) Histamine Receptor (2) Histone Methyltransferase (5) mAChR (2) Monoamine Oxidase (1) Neuropeptide S Receptor (1) Neuropeptide Y Receptor (1) NO Synthase (2) Opioid Receptor (6) Orexin Receptor (OX Receptor) (2) Sigma Receptor (3) Tyrosinase (1)
By Research Areas:	Cancer (6) Endocrinology (7) Metabolic Disease (2) Neurological Disease (37)

By Targets:

5-HT Receptor (3)

Adrenergic Receptor (6)

Cannabinoid Receptor (2)

Cholinesterase (ChE) (1)

Dopamine Receptor (16)

Dopamine Transporter (1)

Drug Intermediate (1)

Drug Isomer (1)

EAAT (1)

GABA Receptor (1)

HDAC (1)

Histamine Receptor (2)

Histone Methyltransferase (5)

mAChR (2)

Monoamine Oxidase (1)

Neuropeptide S Receptor (1)

Neuropeptide Y Receptor (1)

NO Synthase (2)

Opioid Receptor (6)

Orexin Receptor (OX Receptor) (2)

Sigma Receptor (3)

Tyrosinase (1)

By Research Areas:

Cancer (6)

Endocrinology (7)

Metabolic Disease (2)

Neurological Disease (37)

Inhibitors & Agonists

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-145454

(R)-Preclamol (+)-3-PPP	Dopamine Receptor	Neurological Disease
(R)-Preclamol is a dopamine (DA) agonist with autoreceptor as well as postsynaptic receptor stimulatory properties. (R)-Preclamol inhibits the locomotor activity of mice and rats in low doses .

HY-P1329A

CTOP TFA 1 Publications Verification	Opioid Receptor	Neurological Disease
CTOP TFA is a potent and highly selective μ-opioid receptor antagonist. CTOP TFA antagonizes the acute analgesic effect and hypermotility. CTOP TFA enhances extracellular dopamine levels in the nucleus accumbens. CTOP TFA dose-dependently enhances locomotor activity .

HY-10895

SB-334867 Maximum Cited Publications 6 Publications Verification SB 334867A	Orexin Receptor (OX Receptor)	Neurological Disease Endocrinology
SB-334867 (SB 334867A) is an excellent,selective and blood–brain barrier permeable orexin-1 (OX1) receptor antagonist, shows selectivity over OX2 (pK_b=7.4), 100-fold over 5-HT_2B, 5-HT_2C with pK_i values of 5.4 and 5.3, respectively . SB-334867 reduces ethanol consumption and inhibits the acquisition of morphine-induced sensitization to locomotor activity in vivo .

HY-10895A

SB-334867 free base Maximum Cited Publications 6 Publications Verification SB334867A free base	Orexin Receptor (OX Receptor)	Neurological Disease Endocrinology
SB-334867 free base (SB334867A free base) is an excellent, selective and blood–brain barrier permeable orexin-1 (OX1) receptor antagonist, shows selectivity over OX2 (pK_b=7.4), 100-fold over 5-HT_2B, 5-HT_2C with pK_i values of 5.4 and 5.3, respectively . SB-334867 reduces ethanol consumption and inhibits the acquisition of morphine-induced sensitization to locomotor activity in vivo .

HY-123440

S3608	Dopamine Receptor	Neurological Disease
S3608 is an atypical dopamine agonist. S3608 dose dependently increase locomotor activity (LA) in rats .

HY-121775

PF-00217830	Dopamine Receptor	Neurological Disease
F-00217830 is an agonist ofDopamine D2 receptor. PF-00217830 inhibits of spontaneous locomotor activity and 2,5-dimethoxy-4-iodoamphetamine-induced head twitches in rats .

HY-168365

(±)-Pellotine hydrochloride	Drug Isomer	Neurological Disease
(±)-Pellotine hydrochloride (Compound 2) is an alkaloid, which is found in L. diffusa and L. fricii. (±)-Pellotine hydrochloride decreases locomotor activity and the amount of rapid eye movement (REM) sleep in mice .

HY-145454A

Preclamol (-)-3-PPP	Dopamine Receptor	Neurological Disease
Preclamol is a dopamine (DA) agonist with autoreceptor as well as postsynaptic receptor stimulatory properties. Preclamol inhibits the locomotor activity of mice and rats in low doses .

HY-118461

PD 120697	Dopamine Receptor	Neurological Disease
PD 120697 is an orally active dopamine (DA) agonist. PD 120697 inhibits striatal DA synthesis, DA neuronal firing, spontaneous locomotor activity, and reverses Reserpine (HY-N0480)-induced depression .

HY-P1329

CTOP	Opioid Receptor	Neurological Disease
CTOP is a potent and highly selective μ-opioid receptor antagonist. CTOP antagonizes the acute morphine-induced analgesic effect and hypermotility. CTOP enhances extracellular dopamine levels in the nucleus accumbens. CTOP dose-dependently enhances locomotor activity .

HY-103496

U-90042	GABA Receptor	Others
U-90042 is a gamma-aminobutyric acidA receptor agonist of α1, α3 and α6 subtypes with K_i values of 7.8 nM, 9.5 nM and 11.0 nM, respectively. U-90042 suppresses locomotor activity and impairs rotarod performance in mice. U-90042 produces sedation and ataxia and prolongs sleeping time in mice, rats and monkeys. U-90042 can be used as a sedative and hypnotic agent .

HY-105637

Cropropamide Propylbutamide	Drug Intermediate	Neurological Disease
Cropropamide is a component of the respiratory stimulant Prethamide. Cropropamide increases locomotor activity in rats .

HY-101102

7-Hydroxy-DPAT hydrobromide	Dopamine Receptor	Neurological Disease
7-Hydroxy-DPAT hydrobromide is a selective D3 dopamine receptor agonist, exhibiting significant pharmacological activity in modulating locomotor behavior and dopamine metabolism within the brain.

HY-116773

A-69024	Dopamine Receptor	Neurological Disease
A-69024 is a selectivity dopamine D-1 receptor antagonist with the K_i values of 12.6 nM and 1290 nM for dopamine D-1 receptor and dopamine D-2 receptor, respectively .

HY-118402

PD 119819	Dopamine Receptor	Neurological Disease
PD 119819 is a highly selective benzopyran-4-one brain dopamine autoreceptor agonist. PD 119819, a heterocyclic piperazine, inhibits spontaneous locomotor activity and brain dopamine synthesis .

HY-15451

MDA 19 1 Publications Verification	Cannabinoid Receptor	Neurological Disease
MDA 19 is a potent and selective agonist of human cannabinoid receptor 2 (CB2), with a K_i of 43.3 nM. MDA 19 has antiallodynic effects in a rat model of neuropathic pain and does not affect rat locomotor activity .

HY-102062A

Nω-Propyl-L-arginine hydrochloride 1 Publications Verification N-omega-Propyl-L-arginine hydrochloride	NO Synthase	Neurological Disease
Nω-Propyl-L-arginine (N-omega-Propyl-L-arginine) hydrochloride is a potent, competitive, and highly selective inhibitor of neuronal nitric oxide synthase (nNOS), with a K_i of 57 nM. Nω-Propyl-L-arginine hydrochloride displays a 149-fold selectivity for nNOS over endothelial NOS (eNOS) .

HY-102062

Nω-Propyl-L-arginine 1 Publications Verification N-omega-Propyl-L-arginine	NO Synthase	Neurological Disease
Nω-Propyl-L-arginine (N-omega-Propyl-L-arginine) is a potent, competitive, and highly selective inhibitor of neuronal nitric oxide synthase (nNOS), with a K_i of 57 nM. Nω-Propyl-L-arginine displays a 149-fold selectivity for nNOS over endothelial NOS (eNOS) .

HY-14222

UMB24	Sigma Receptor	Neurological Disease
UMB24 is a potent antagonist of σ2 receptor, with K_i values of 170 nM anf 322 nM for σ2 receptor and σ1 receptor, respectively. UMB24 attenuats cocaine-induced convulsions and locomotor activity, but not lethality .

HY-W015616

Benzylacetone 4-Penylbutan-2-one	Tyrosinase	Metabolic Disease
Benzylacetone is an aromatic compound from agarwood . Benzylacetone exhibits potent and reversible antityrosinase (mushroom) activity， with IC₅₀s of 2.8 mM and 0.6 mM for monophenolase and diphenolase, respectively . Benzylacetone has appetite-enhancing and locomotor-reducing effects .

HY-107055

RTI 336	Dopamine Transporter	Neurological Disease
RTI 336 is a phenyltropane analog, as well as a potent and selective dopamine transporter (DAT) inhibitor. RTI 336 inhibits addictive agent induced locomotor activity and self-administration in Lewis rats. RTI 336 exhibits inhibitory effects depending on inherent NAc DAT levels .

HY-P1438A

Neuropeptide S(Rat) TFA	Neuropeptide Y Receptor	Neurological Disease
Neuropeptide S(Rat) TFA is a potent endogenous neuropeptide S receptor (NSPR) agonist (EC₅₀=3.2 nM). Neuropeptide S(Rat) TFA increases locomotor activity and wakefulness in mice. Neuropeptide S(Rat) TFA also reduces anxiety-like behavior in mice.

HY-107751

BW373U86 SNC86	Opioid Receptor	Neurological Disease
BW373U86 (SNC86) is a δ-opioid receptor agonist with an IC₅₀ of 1.49 nM. BW373U86 shows antidepressant-like effects .

HY-170654

Opioid receptor antagonist 1	Opioid Receptor	Neurological Disease
Opioid receptor antagonist 1 (Compound 10) is an Orvinol (HY-D0168)-based opioid receptor antagonist. Opioid receptor antagonist 1 has antagonistic activity to the analgesic properties of Morphine .

HY-108510

Rimcazole dihydrochloride BW 234U dihydrochloride	Sigma Receptor Dopamine Receptor	Neurological Disease Cancer
Rimcazole (BW 234U) dihydrochloride is a carbazole derivative that acts in part as a sigma (σ) receptor antagonist. Rimcazole dihydrochloride also binds with moderate affinity to the dopamine transporter and inhibit dopamine uptake. Rimcazole dihydrochloride can reduce locomotor activity and sensitization. Rimcazole dihydrochloride also can be used for the research of cancer .

HY-15451R

MDA 19 (Standard)	Cannabinoid Receptor	Neurological Disease
MDA 19 (Standard) is the analytical standard of MDA 19. This product is intended for research and analytical applications. MDA 19 is a potent and selective agonist of human cannabinoid receptor 2 (CB2), with a Ki of 43.3 nM. MDA 19 has antiallodynic effects in a rat model of neuropathic pain and does not affect rat locomotor activity .

HY-P1437A

Neuropeptide S(Mouse) TFA	Neuropeptide S Receptor	Neurological Disease
Neuropeptide S(Mouse) TFA is a potent endogenous neuropeptide S receptor (NPSR) agonist (EC₅₀=3 nM). Neuropeptide S(Mouse) TFA induces mobilization of intracellular Ca ²⁺. Neuropeptide S(Mouse) TFA increases locomotor activity and wakefulness in mice. Neuropeptide S(Mouse) TFA also reduces anxiety-like behavior in mice.

HY-168334

5-HT2C agonist-4	5-HT Receptor	Neurological Disease
5-HT2C agonist-4 (Compound 3i) is an agonist for 5-HT2C receptor with an EC₅₀ of 5.7 nM. 5-HT2C agonist-4 reduces locomotor activity in the zebrafish larval model .

HY-P1318

Ac-RYYRIK-NH2	Opioid Receptor	Neurological Disease
Ac-RYYRIK-NH2 is a potent and partial agonist on ORL1 transfected in CHO cells (K_d=1.5 nM) and behaves as a endogenous ligand of ORL1. Ac-RYYRIK-NH2 is a specific antagonist for the activation of G protein and competitively antagonizes the stimulation of [ ³⁵S]-GTPgS binding to G proteins by nociceptin/orphanin FQ (noc/OFQ) in membranes and sections of rat brain .

HY-149247

Antipsychotic agent-2	5-HT Receptor Dopamine Receptor	Neurological Disease
Antipsychotic agent-2 (Compound 11) is a potent antipsychotic agent. Antipsychotic agent-2 shows affinities for 5-HT_1A, 5-HT_2A, 5-HT_2C, D₂ and H₁ receptors with K_is of 56.6, 66.7, 552, 596 and 1140 nM, respectively. Antipsychotic agent-2 has BBB permeability .

HY-P1318A

Ac-RYYRIK-NH2 TFA	Opioid Receptor	Neurological Disease
Ac-RYYRIK-NH2 TFA is a potent and partial agonist on ORL1 transfected in CHO cells (K_d=1.5 nM) and behaves as a endogenous ligand of ORL1. Ac-RYYRIK-NH2 is a specific antagonist for the activation of G protein and competitively antagonizes the stimulation of [ ³⁵S]-GTPgS binding to G proteins by nociceptin/orphanin FQ (noc/OFQ) in membranes and sections of rat brain .

HY-12707C

Piribedil hydrochloride	Dopamine Receptor Adrenergic Receptor Histone Methyltransferase	Neurological Disease Endocrinology Cancer
Piribedil hydrochloride is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil hydrochloride is also a α2-adrenoceptors antagonist. Piribedil hydrochloride can inhibit MLL1 methyltransferase activity (EC₅₀: 0.18 μM). Piribedil hydrochloride has the potential for the research of parkinson's disease, circulatory disorders, cancers .

HY-12707

Piribedil 1 Publications Verification	Dopamine Receptor Adrenergic Receptor Histone Methyltransferase	Neurological Disease Endocrinology Cancer
Piribedil is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil is also a α2-adrenoceptors antagonist. Piribedil can inhibit MLL1 methyltransferase activity (EC₅₀: 0.18 μM). Piribedil has the potential for the research of parkinson's disease, circulatory disorders, cancers .

HY-12707A

Piribedil dihydrochloride	Adrenergic Receptor Dopamine Receptor Histone Methyltransferase	Neurological Disease Endocrinology Cancer
Piribedil dihydrochloride is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil dihydrochloride is also a α2-adrenoceptors antagonist. Piribedil dihydrochloride can inhibit MLL1 methyltransferase activity (EC₅₀: 0.18 μM). Piribedil dihydrochloride has the potential for the research of parkinson's disease, circulatory disorders, cancers .

HY-12707B

Piribedil maleate	Dopamine Receptor Adrenergic Receptor Histone Methyltransferase	Neurological Disease Endocrinology Cancer
Piribedil maleate is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil maleate is also a α2-adrenoceptors antagonist. Piribedil maleate can inhibit MLL1 methyltransferase activity (EC₅₀: 0.18 μM). Piribedil maleate has the potential for the research of parkinson's disease, circulatory disorders, cancers .

HY-12707R

Piribedil (Standard)	Dopamine Receptor Adrenergic Receptor Histone Methyltransferase	Neurological Disease Endocrinology Cancer
Piribedil (Standard) is the analytical standard of Piribedil. This product is intended for research and analytical applications. Piribedil is a potent and orally active dopamine D2 and dopamine D3 agonist. Piribedil is also a α2-adrenoceptors antagonist. Piribedil can inhibit MLL1 methyltransferase activity (EC₅₀: 0.18 μM). Piribedil has the potential for the research of parkinson's disease, circulatory disorders, cancers .

HY-168773

(R)-AS-1	EAAT	Neurological Disease
(R)-AS-1 is a selective positive allosteric modulator of the excitatory amino acid transporter 2 (EAAT2), with an EC₅₀ of 11 nM. (R)-AS-1 (at doses of 60 and 90 mg/kg) increases spontaneous locomotor activity in mice. Additionally, it demonstrates anticonvulsant activity in mouse models of seizures induced by maximal electroshock (MES), pentylenetetrazole (PTZ), or electrical stimuli (32 or 44 mA), with ED₅₀s of 66.3, 36.3, 15.6, and 41.6 mg/kg, respectively. (R)-AS-1 can be used in neurological disease research .

HY-117408

VU6004256	mAChR	Neurological Disease
VU6004256 is a potent and selective M1 muscarinic positive allosteric modulator (PAM) with an EC₅₀ value of 155 nM. VU6004256 has the potential for the research of schizophrenia .

HY-169156

HDAC6-IN-49	HDAC Monoamine Oxidase Cholinesterase (ChE) Histamine Receptor 5-HT Receptor	Neurological Disease
HDAC6-IN-49 (Compound 3) is an inhibitor for HDAC with IC₅₀ of 0.012 and 0.735 μM for HDAC6 and HDAC1. HDAC6-IN-49 also exhibits inhibitory activities against MAO-B, cholinesterase (ChE), histamine receptor (H3R) and serotonin 6 receptor (5-HT6R). HDAC6-IN-49 exhibits neuroprotective efficacy on SH-SY5Y cell. HDAC6-IN-49 improves cognitive function and locomotor ability in Drosophila Parkinson's disease models and in C. elegans Alzheimer's disease models .

HY-A0139

Thiothixene NSC 108165; Navan; Navane	Sigma Receptor mAChR Histamine Receptor Dopamine Receptor Adrenergic Receptor	Others
Thiothixene is a typical antipsychotic. It selectively binds to dopamine D2 over D1, D3, and D4 receptors (Kis=0.417, 338, 186.2, and 363.1 nM, respectively). Thiothixene also binds to various serotonin (5-HT), histamine H1, α1- and α2-adrenergic, muscarinic acetylcholine, and sigma receptors (Kis=15-5,754 nM) as well as the dopamine, norepinephrine, and serotonin transporters (Kis=3.16-30 μM). In vivo, thiothixene reduces spontaneous and amphetamine-induced locomotor activity in rats. It enhances latent inhibition, as measured by a decreased lick latency in response to light and foot shock stimuli, which is a measure of selective attention in rats.3 Thiothixene also increases competitive behavior in submissive mice, indicating antidepressant-like behavior.

Cat. No.	Product Name	Target	Research Area